ClinicalTrials.gg
CompletedNCT00237211Updated Nov 14, 2018

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

A Phase 2 interventional study of Letrozole in Postmenopausal Women With Advanced Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in Japan. Open to female participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
20 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Enrollment
122nd of 159
31 · median 95
Started
2001
with 1 other
Phase 2
72 of 162
13 open now
Registered
18th of 162
by date
Lead sponsor
21 of 162
Novartis Pharmaceuticals

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 122nd largest by enrollment of the 159 interventional ones that give a count, is one of 2 that started in 2001, is one of 72 in phase 2, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 20 Years to 74 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

To investigate the safety and efficacy of letrozole monotherapy at a dose of 2.5 mg/day in postmenopausal patients with breast cancer, and to determine the blood concentrations of letrozole and hormones.

03

Conditions studied

  • Postmenopausal Women With Advanced Breast Cancer

Browse trials for

Keywords

  • Aromatase inhibitor
  • letrozole
  • breast cancer
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with documented breast cancer.
  • Patients with hormone receptor (ER and/or PgR) status of positive or unknown
  • Patients who have been amenorrheic for the preceding 12 months or more.
  • Patients who are 20 years or older and younger than 75 years.
  • Patients with a history of postoperative therapy or a history of endocrine therapy with tamoxifen for the treatment of progression or recurrence of the lesion. The endocrine therapy, however, should not exceed one regimen.
  • Patients with progressing lesions.
  • Patients with sufficient organ function to evaluate the safety
  • Patients whose performance status (PS) is classified in 0~2.
  • Patients who have no residual effects from previous treatments

Exclusion criteria

Exclusion Criteria:

  • Patients with other concurrent or previous malignant disease (excluding uterine carcinoma in-situ).
  • Patients with hypercalcemia and uncontrollable cardiac disease (including a history of serious cardiac disease)
  • Patients who have previously received aromatase inhibitor.
  • Patients who have lymphangitis-type lung or symptomatic .

Other protocol-defined inclusion / exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Letrozole

    Drug: Letrozole

Interventions

06

What researchers measure

Primary outcomes

  1. Safety during treatment

    Time frame: Until disease progression or appearance of unacceptable toxicity whichever comes first

  2. Response Rate during treatment

    Time frame: Until disease progression or appearance of unacceptable toxicity whichever comes first

Secondary outcomes

  1. Pharmacokinetics measurement at baseline and at every 4 weeks until 28 weeks

    Time frame: Maximum 28 weeks after initiate treatment

  2. Plasma estrogens level at baseline and at every 4 weeks until 28 weeks

    Time frame: Maximum 28 weeks after initiate treatment

  3. Duration of response

    Time frame: From the first date of response confirmed and the last date of response confirmed

  4. Time to progression

    Time frame: From the first date of response confirmed and the last date of response confirmed

07

Study locations

12 sites
  • Novartis Investigative Site
    Kashiwa, Chiba 277-8577, Japan
  • Novartis Investigative Site
    Matsuyama, Ehime 791-0280, Japan
  • Novartis Investigative Site
    Kooriyama, Fukushima 963-8501, Japan
  • Novartis Investigative Site
    Maebashi, Gunma 371-8511, Japan
  • Novartis Investigative Site
    Kurashiki, Okayama 701-0192, Japan
  • Novartis Investigative Site
    Kitaadachi-gun, Saitama 338-8553, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8677, Japan
  • Novartis Investigative Site
    Chuo-ku, Tokyo 104-0045, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Novartis Investigative Site
    Fukushima, 960-1295, Japan
  • Novartis Investigative Site
    Osaka, 537-8511, Japan
  • Novartis Investigative Site
    Saitama, 338-8553, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2001, a primary completion of Oct 2006 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2005
First posted
Oct 12, 2005
Start
Jun 2001
Primary completionActual
Oct 2006
CompletionActual
Oct 2006
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00237211
Responsible party
Sponsor
First posted
Oct 12, 2005
Start date
Jun 2001
Primary completion
Oct 2006
Completion
Oct 2006
Last update
Nov 14, 2018

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion